4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2026)
4D Molecular Therapeutics (FDMT) reported Treasury Shares of $1.6 million for Q1 2026, up 113.08% year-over-year from $748380.0 in Q1 2025, and up 114.11% quarter-over-quarter from $744770.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 4 years of Treasury Shares data on file, last reported at $1.6 million in Q1 2026.
- Treasury Shares for Q1 2026 came in at $1.6 million, up 113.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 113.08% YoY), and the FY2025 annual result was $744770.0, up 105.74% from the prior year.
- Treasury Shares climbed to $1.6 million in Q1 2026 per FDMT's latest filing, from $744770.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $1.6 million in Q1 2026 and troughed at $181181.0 in Q4 2023.
- A 4-year average of $585078.7 and a median of $530008.0 in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2025: Treasury Shares jumped 99.8% in 2024, then jumped 256.54% in 2025.
- A 4-year view of Treasury Shares shows it stood at $181181.0 in 2023, then surged by 99.8% to $361997.0 in 2024, then soared by 105.74% to $744770.0 in 2025, then soared by 114.11% to $1.6 million in 2026.
- Business Quant data shows FDMT's Treasury Shares at $1.6 million in Q1 2026, $744770.0 in Q4 2025, and $698019.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | 1.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.59 Mn |
| Mar 31, 2026 | 1.59 Mn |
| Dec 31, 2025 | 744,770.00 |
| Dec 31, 2025 | 744,770.00 |
| Sep 30, 2025 | 698,019.00 |
| Sep 30, 2025 | 698,019.00 |
| Jun 30, 2025 | 725,101.00 |
| Jun 30, 2025 | 725,101.00 |
| Mar 31, 2025 | 748,380.00 |
| Mar 31, 2025 | 748,380.00 |
| Dec 31, 2024 | 361,997.00 |
| Dec 31, 2024 | 361,997.00 |
| Sep 30, 2024 | 328,667.00 |
| Sep 30, 2024 | 328,667.00 |
| Jun 30, 2024 | 258,117.00 |
| Jun 30, 2024 | 258,117.00 |
| Mar 31, 2024 | 209,900.00 |
| Mar 31, 2024 | 209,900.00 |
| Dec 31, 2023 | 181,181.00 |
| Dec 31, 2023 | 181,181.00 |